MinervaX

Executive Summary

MinervaX is a private, clinical-stage vaccine company focused on developing a prophylactic vaccine against Group B Streptococcus (GBS), a leading cause of life-threatening infections in newborns. The company's proprietary vaccine candidate utilizes a novel fusion protein technology designed to target multiple GBS serotypes, aiming to provide broad protection. By preventing maternal GBS colonization, the vaccine seeks to reduce vertical transmission to infants. Founded in 2015 and headquartered in Cambridge, Massachusetts, MinervaX has raised approximately $126 million to date and is currently in Phase 2 clinical development. The company's approach addresses a significant unmet medical need, as GBS is a major cause of neonatal sepsis and meningitis worldwide, with no licensed vaccine currently available. MinervaX's platform has the potential to become a standard-of-care in maternal immunization, offering both public health impact and substantial commercial opportunity.

Upcoming Catalysts (preview)

• H2 2026Phase 2 Efficacy Data Readout70% success
• Q1 2027Strategic Partnership for Phase 3 Development60% success
• Q4 2026FDA Meeting for Phase 3 Trial Design80% success